PRESTIGE CONSUMER HEALTHCARE (PBH) Stock Fundamental Analysis

NYSE:PBH • US74112D1019

66.79 USD
-0.17 (-0.25%)
At close: Feb 13, 2026
66.79 USD
0 (0%)
After Hours: 2/13/2026, 8:04:00 PM
Overview Stock Chart Technical Analysis Fundamental Analysis Analyst Ratings Earnings Estimates Financials Ownership News
Fundamental Rating

6

Overall PBH gets a fundamental rating of 6 out of 10. We evaluated PBH against 191 industry peers in the Pharmaceuticals industry. PBH scores excellent points on both the profitability and health parts. This is a solid base for a good stock. PBH is valued correctly, but it does not seem to be growing.


Dividend Valuation Growth Profitability Health

7

1. Profitability

1.1 Basic Checks

  • In the past year PBH was profitable.
  • In the past year PBH had a positive cash flow from operations.
  • PBH had positive earnings in 4 of the past 5 years.
  • Each year in the past 5 years PBH had a positive operating cash flow.
PBH Yearly Net Income VS EBIT VS OCF VS FCFPBH Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 100M 200M 300M

1.2 Ratios

  • Looking at the Return On Assets, with a value of 5.83%, PBH belongs to the top of the industry, outperforming 86.91% of the companies in the same industry.
  • With an excellent Return On Equity value of 11.00%, PBH belongs to the best of the industry, outperforming 85.86% of the companies in the same industry.
  • PBH has a better Return On Invested Capital (7.88%) than 86.39% of its industry peers.
  • PBH had an Average Return On Invested Capital over the past 3 years of 8.16%. This is below the industry average of 12.64%.
Industry RankSector Rank
ROA 5.83%
ROE 11%
ROIC 7.88%
ROA(3y)3.39%
ROA(5y)4.11%
ROE(3y)6.22%
ROE(5y)8.76%
ROIC(3y)8.16%
ROIC(5y)7.67%
PBH Yearly ROA, ROE, ROICPBH Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 10 20

1.3 Margins

  • PBH's Profit Margin of 18.09% is amongst the best of the industry. PBH outperforms 90.05% of its industry peers.
  • PBH's Profit Margin has improved in the last couple of years.
  • Looking at the Operating Margin, with a value of 31.00%, PBH belongs to the top of the industry, outperforming 94.24% of the companies in the same industry.
  • In the last couple of years the Operating Margin of PBH has remained more or less at the same level.
  • PBH has a better Gross Margin (56.10%) than 68.06% of its industry peers.
  • PBH's Gross Margin has been stable in the last couple of years.
Industry RankSector Rank
OM 31%
PM (TTM) 18.09%
GM 56.1%
OM growth 3Y0.37%
OM growth 5Y-0.32%
PM growth 3Y-0.06%
PM growth 5Y5%
GM growth 3Y-0.79%
GM growth 5Y-0.88%
PBH Yearly Profit, Operating, Gross MarginsPBH Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 20 40

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

7

2. Health

2.1 Basic Checks

  • With a Return on Invested Capital (ROIC) below the Cost of Capital (WACC), PBH is destroying value.
  • The number of shares outstanding for PBH has been reduced compared to 1 year ago.
  • The number of shares outstanding for PBH has been reduced compared to 5 years ago.
  • Compared to 1 year ago, PBH has an improved debt to assets ratio.
PBH Yearly Shares OutstandingPBH Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 10M 20M 30M 40M 50M
PBH Yearly Total Debt VS Total AssetsPBH Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 1B 2B 3B

2.2 Solvency

  • PBH has an Altman-Z score of 2.62. This is not the best score and indicates that PBH is in the grey zone with still only limited risk for bankruptcy at the moment.
  • PBH's Altman-Z score of 2.62 is fine compared to the rest of the industry. PBH outperforms 66.49% of its industry peers.
  • The Debt to FCF ratio of PBH is 3.97, which is a good value as it means it would take PBH, 3.97 years of fcf income to pay off all of its debts.
  • PBH has a better Debt to FCF ratio (3.97) than 86.91% of its industry peers.
  • PBH has a Debt/Equity ratio of 0.55. This is a neutral value indicating PBH is somewhat dependend on debt financing.
  • With a Debt to Equity ratio value of 0.55, PBH is not doing good in the industry: 65.44% of the companies in the same industry are doing better.
Industry RankSector Rank
Debt/Equity 0.55
Debt/FCF 3.97
Altman-Z 2.62
ROIC/WACC0.9
WACC8.76%
PBH Yearly LT Debt VS Equity VS FCFPBH Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 500M 1B 1.5B 2B

2.3 Liquidity

  • PBH has a Current Ratio of 3.70. This indicates that PBH is financially healthy and has no problem in meeting its short term obligations.
  • Looking at the Current ratio, with a value of 3.70, PBH is in line with its industry, outperforming 56.54% of the companies in the same industry.
  • A Quick Ratio of 2.51 indicates that PBH has no problem at all paying its short term obligations.
  • PBH's Quick ratio of 2.51 is in line compared to the rest of the industry. PBH outperforms 51.31% of its industry peers.
Industry RankSector Rank
Current Ratio 3.7
Quick Ratio 2.51
PBH Yearly Current Assets VS Current LiabilitesPBH Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 100M 200M 300M 400M

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

3

3. Growth

3.1 Past

  • PBH shows a small growth in Earnings Per Share. In the last year, the EPS has grown by 6.92%.
  • Measured over the past years, PBH shows a quite strong growth in Earnings Per Share. The EPS has been growing by 8.88% on average per year.
  • Looking at the last year, PBH shows a small growth in Revenue. The Revenue has grown by 1.10% in the last year.
  • PBH shows a small growth in Revenue. Measured over the last years, the Revenue has been growing by 3.39% yearly.
EPS 1Y (TTM)6.92%
EPS 3Y3.72%
EPS 5Y8.88%
EPS Q2Q%-6.56%
Revenue 1Y (TTM)1.1%
Revenue growth 3Y1.54%
Revenue growth 5Y3.39%
Sales Q2Q%-2.37%

3.2 Future

  • Based on estimates for the next years, PBH will show a small growth in Earnings Per Share. The EPS will grow by 4.28% on average per year.
  • Based on estimates for the next years, PBH will show a small growth in Revenue. The Revenue will grow by 0.71% on average per year.
EPS Next Y1.56%
EPS Next 2Y3.7%
EPS Next 3Y3.57%
EPS Next 5Y4.28%
Revenue Next Year-2.1%
Revenue Next 2Y0.04%
Revenue Next 3Y0.72%
Revenue Next 5Y0.71%

3.3 Evolution

  • The EPS growth rate is decreasing: in the next years the growth will be less than in the last years.
  • When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is decreasing.
PBH Yearly Revenue VS EstimatesPBH Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 200M 400M 600M 800M 1B
PBH Yearly EPS VS EstimatesPBH Yearly EPS VS EstimatesYearly EPS VS Estimates 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 0 2 4

More info and screens

Find the best growth stocksShow best growing peers

6

4. Valuation

4.1 Price/Earnings Ratio

  • With a Price/Earnings ratio of 14.91, PBH is valued correctly.
  • PBH's Price/Earnings ratio is rather cheap when compared to the industry. PBH is cheaper than 87.96% of the companies in the same industry.
  • The average S&P500 Price/Earnings ratio is at 26.68. PBH is valued slightly cheaper when compared to this.
  • A Price/Forward Earnings ratio of 13.71 indicates a correct valuation of PBH.
  • PBH's Price/Forward Earnings ratio is rather cheap when compared to the industry. PBH is cheaper than 84.82% of the companies in the same industry.
  • PBH is valuated cheaply when we compare the Price/Forward Earnings ratio to 28.06, which is the current average of the S&P500 Index.
Industry RankSector Rank
PE 14.91
Fwd PE 13.71
PBH Price Earnings VS Forward Price EarningsPBH Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 10 20 30

4.2 Price Multiples

  • PBH's Enterprise Value to EBITDA ratio is rather cheap when compared to the industry. PBH is cheaper than 88.48% of the companies in the same industry.
  • 88.48% of the companies in the same industry are more expensive than PBH, based on the Price/Free Cash Flow ratio.
Industry RankSector Rank
P/FCF 12.37
EV/EBITDA 10.85
PBH Per share dataPBH EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 10 -10 20 -20 30

4.3 Compensation for Growth

  • The high PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates PBH does not grow enough to justify the current Price/Earnings ratio.
  • PBH has a very decent profitability rating, which may justify a higher PE ratio.
PEG (NY)9.57
PEG (5Y)1.68
EPS Next 2Y3.7%
EPS Next 3Y3.57%

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

0

5. Dividend

5.1 Amount

  • No dividends for PBH!.
Industry RankSector Rank
Dividend Yield 0%

More info and screens

Find the best dividend stocksShow peers with best dividend

PRESTIGE CONSUMER HEALTHCARE

NYSE:PBH (2/13/2026, 8:04:00 PM)

After market: 66.79 0 (0%)

66.79

-0.17 (-0.25%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)02-05
Earnings (Next)05-06
Inst Owners108.83%
Inst Owner Change-93.66%
Ins Owners1.31%
Ins Owner Change-0.48%
Market Cap3.16B
Revenue(TTM)1.14B
Net Income(TTM)200.84M
Analysts84
Price Target78.03 (16.83%)
Short Float %4.37%
Short Ratio5.11
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)1.61%
Min EPS beat(2)-5.96%
Max EPS beat(2)9.18%
EPS beat(4)3
Avg EPS beat(4)2.04%
Min EPS beat(4)-5.96%
Max EPS beat(4)9.18%
EPS beat(8)5
Avg EPS beat(8)-0.36%
EPS beat(12)7
Avg EPS beat(12)-46.48%
EPS beat(16)11
Avg EPS beat(16)-33.78%
Revenue beat(2)1
Avg Revenue beat(2)0.1%
Min Revenue beat(2)-5.34%
Max Revenue beat(2)5.55%
Revenue beat(4)3
Avg Revenue beat(4)0.5%
Min Revenue beat(4)-5.34%
Max Revenue beat(4)5.55%
Revenue beat(8)4
Avg Revenue beat(8)-0.19%
Revenue beat(12)5
Avg Revenue beat(12)-0.15%
Revenue beat(16)9
Avg Revenue beat(16)0.5%
PT rev (1m)-1.29%
PT rev (3m)-5.32%
EPS NQ rev (1m)0.63%
EPS NQ rev (3m)-7.48%
EPS NY rev (1m)-0.08%
EPS NY rev (3m)0.88%
Revenue NQ rev (1m)0.31%
Revenue NQ rev (3m)-2.11%
Revenue NY rev (1m)-0.09%
Revenue NY rev (3m)0.27%
Valuation
Industry RankSector Rank
PE 14.91
Fwd PE 13.71
P/S 2.85
P/FCF 12.37
P/OCF 12
P/B 1.73
P/tB N/A
EV/EBITDA 10.85
EPS(TTM)4.48
EY6.71%
EPS(NY)4.87
Fwd EY7.29%
FCF(TTM)5.4
FCFY8.08%
OCF(TTM)5.57
OCFY8.34%
SpS23.47
BVpS38.57
TBVpS-21.02
PEG (NY)9.57
PEG (5Y)1.68
Graham Number62.35
Profitability
Industry RankSector Rank
ROA 5.83%
ROE 11%
ROCE 10.41%
ROIC 7.88%
ROICexc 8.17%
ROICexgc 70.59%
OM 31%
PM (TTM) 18.09%
GM 56.1%
FCFM 23%
ROA(3y)3.39%
ROA(5y)4.11%
ROE(3y)6.22%
ROE(5y)8.76%
ROIC(3y)8.16%
ROIC(5y)7.67%
ROICexc(3y)8.33%
ROICexc(5y)7.8%
ROICexgc(3y)85.26%
ROICexgc(5y)93.76%
ROCE(3y)10.78%
ROCE(5y)10.14%
ROICexgc growth 3Y-14.1%
ROICexgc growth 5Y-7.82%
ROICexc growth 3Y5.03%
ROICexc growth 5Y3.52%
OM growth 3Y0.37%
OM growth 5Y-0.32%
PM growth 3Y-0.06%
PM growth 5Y5%
GM growth 3Y-0.79%
GM growth 5Y-0.88%
F-Score7
Asset Turnover0.32
Health
Industry RankSector Rank
Debt/Equity 0.55
Debt/FCF 3.97
Debt/EBITDA 2.71
Cap/Depr 27.11%
Cap/Sales 0.72%
Interest Coverage 7.8
Cash Conversion 70.49%
Profit Quality 127.19%
Current Ratio 3.7
Quick Ratio 2.51
Altman-Z 2.62
F-Score7
WACC8.76%
ROIC/WACC0.9
Cap/Depr(3y)27.42%
Cap/Depr(5y)37.16%
Cap/Sales(3y)0.75%
Cap/Sales(5y)1.1%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)6.92%
EPS 3Y3.72%
EPS 5Y8.88%
EPS Q2Q%-6.56%
EPS Next Y1.56%
EPS Next 2Y3.7%
EPS Next 3Y3.57%
EPS Next 5Y4.28%
Revenue 1Y (TTM)1.1%
Revenue growth 3Y1.54%
Revenue growth 5Y3.39%
Sales Q2Q%-2.37%
Revenue Next Year-2.1%
Revenue Next 2Y0.04%
Revenue Next 3Y0.72%
Revenue Next 5Y0.71%
EBIT growth 1Y5.81%
EBIT growth 3Y1.92%
EBIT growth 5Y3.06%
EBIT Next Year6.22%
EBIT Next 3Y3.43%
EBIT Next 5Y2.82%
FCF growth 1Y18.43%
FCF growth 3Y-0.94%
FCF growth 5Y4.02%
OCF growth 1Y17.36%
OCF growth 3Y-1.09%
OCF growth 5Y2.99%

PRESTIGE CONSUMER HEALTHCARE / PBH FAQ

What is the ChartMill fundamental rating of PRESTIGE CONSUMER HEALTHCARE (PBH) stock?

ChartMill assigns a fundamental rating of 6 / 10 to PBH.


Can you provide the valuation status for PRESTIGE CONSUMER HEALTHCARE?

ChartMill assigns a valuation rating of 6 / 10 to PRESTIGE CONSUMER HEALTHCARE (PBH). This can be considered as Fairly Valued.


What is the profitability of PBH stock?

PRESTIGE CONSUMER HEALTHCARE (PBH) has a profitability rating of 7 / 10.


What is the expected EPS growth for PRESTIGE CONSUMER HEALTHCARE (PBH) stock?

The Earnings per Share (EPS) of PRESTIGE CONSUMER HEALTHCARE (PBH) is expected to grow by 1.56% in the next year.